$121.86−1.02 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$119.48−2.38 (−1.95%)
After hours: Nov 17, 2026, 5:11 PM ET
Insmed (INSM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~33.9%/yr (FY21→FY25), net margin −210.5%. Worth your attention in FY25: Share count (+77.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲66.7%
606.4
FY21→FY25CAGR +33.9%/yr
Net income ($M)▼39.7%
−1,276.8
FY21→FY25CAGR —
Free cash flow ($M)▼37.1%
−967.6
FY21→FY25CAGR —
Diluted EPS▼15.3%
−6.42
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+77.5%
112.1mn → 199.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$32.6M
+48.5% YoY in FY25 · 5.4% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-211¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 76.6% → 79.7%. Net margin -210.5% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,519.7 | 606.4 | 363.7 | 305.2 | 245.4 | 188.5 | ▲66.7% | +33.9% |
Cost of revenue | 237.1 | 122.9 | 85.7 | 65.6 | 55.1 | 44.2 | ▲43.4% | +29.2% |
Gross profit | 1,282.7 | 483.5 | 278.0 | 239.6 | 190.2 | 144.3 | ▲73.9% | +35.3% |
Research & development | 944.4 | 771.1 | 598.4 | 571.0 | 397.5 | 272.7 | ▲28.9% | +29.7% |
Selling, general & admin | 960.2 | 701.2 | 461.1 | 344.5 | 265.8 | 234.3 | ▲52.1% | +31.5% |
Total operating expenses | 1,846.6 | 1,730.3 | 1,156.2 | 949.3 | 647.6 | 519.4 | ▲49.6% | +35.1% |
Operating incomefeeds ROC rank | −564.0 | −1,246.8 | −878.3 | −709.6 | −457.3 | −375.1 | ▼42.0% | — |
Other income, net | −34.1 | −25.0 | −31.8 | −37.4 | −22.8 | −61.3 | — | — |
Pretax income | −598.1 | −1,271.7 | −910.1 | −747.0 | −480.2 | −436.4 | ▼39.7% | — |
Income tax | 7.6 | 5.0 | 3.7 | 2.6 | 1.4 | −1.8 | ▲35.6% | +53.7% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −605.6 | −1,276.8 | −913.8 | −749.6 | −481.5 | −434.7 | ▼39.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.83 | −6.42 | −5.57 | −5.34 | −3.91 | −3.88 | ▼15.3% | — |
Diluted shares (mn) | 218.79 | 199.01 | 164.04 | 140.43 | 123.03 | 112.11 | ▲21.3% | +15.4% |
| Margins | ||||||||
Gross margin78th pct in Healthcare | 84.4% | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | ▲3.3pp | +3.2pp |
Operating margin | −37.1% | −205.6% | −241.5% | −232.5% | −186.4% | −199.0% | ▲35.9pp | −6.6pp |
Net margin16th pct in Healthcare | −39.9% | −210.5% | −251.2% | −245.6% | −196.3% | −230.6% | ▲40.7pp | +20.1pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Insmed's revenue last fiscal year?
Insmed reported revenue of $606.4M in fiscal 2025, up 66.7% from fiscal 2024.
What was Insmed's net income?
Insmed reported net income of −$1,276.8M in fiscal 2025, a net margin of −210.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

